Higher compared to lower consumption of omega-3 fatty acids from fish and seafood in type 2 diabetes

Reading time approx. 1 minute
This page contains 1 evidence gap
  1. Higher compared to lower consumption of omega-3 fatty acids from fish and seafood in type 2 diabetes
Population:
Adults, from 18 years, with diabetes type 2
Exposure:
Higher consumption of omega-3 fatty acids from fish and seafood
Comparison:
Lower consumption of omega-3 fatty acids from fish and seafood
Outcomes:
• Mortality (total and cause-specific mortality)
• Morbidity (total morbidity, diabetes complications, need for drug treatment, osteoporosis)
• Diabetes remission
• Quality of life (e.g. EQ-5D, SF-6D, SF-36)
• Side effects (e.g. hypo- or hyperglycemia).

What evidence is needed?

More primary research is needed.

What evidence is available?

Reliable systematic reviews that show evidence gaps:

SBU. Mat vid diabetes [Diets for diabetes: a systematic review and assessment of effects, health economic and ethical aspects]. Stockholm: Statens beredning för medicinsk och social utvärdering (SBU); 2022. SBU Utvärderar 345. More about the review

Reliable, but not updated, systematic reviews that show evidence gaps:

None identified

Registration number:
Published:
Research conducted after publication could potentially change the nature of the evidence.
To top

Evidence gap identifies methods or practices for which no conclusive systematic review of benefits and harms has been published. Gaps in scientific evidence appear on the SBU website to help researchers and granting agencies identify areas that are in need of research or systematic review. An additional objective is to offer healthcare and social service providers a basis for setting priorities.